Late stage infection in sleeping sickness

At the turn of the 19(th) century, trypanosomes were identified as the causative agent of sleeping sickness and their presence within the cerebrospinal fluid of late stage sleeping sickness patients was described. However, no definitive proof of how the parasites reach the brain has been presented so far. Analyzing electron micrographs prepared from rodent brains more than 20 days after infection, we present here conclusive evidence that the parasites first enter the brain via the choroid plexus from where they penetrate the epithelial cell layer to reach the ventricular system. Adversely, no trypanosomes were observed within the parenchyma outside blood vessels. We also show that brain infection depends on the formation of long slender trypanosomes and that the cerebrospinal fluid as well as the stroma of the choroid plexus is a hostile environment for the survival of trypanosomes, which enter the pial space including the Virchow-Robin space via the subarachnoid space to escape degradation. Our data suggest that trypanosomes do not intend to colonize the brain but reside near or within the glia limitans, from where they can re-populate blood vessels and disrupt the sleep wake cycles.     

Neurobiology of sleeping sickness

The advanced stages of sleeping sickness are correlated with a spread of trypanosomes into the central nervous system (CNS), producing a disseminated encephalitis. Inflammatory reactions extend along the blood vessels causing perivascular cuffing, which consists of in filtrations and proliferations of lymphocytes and also increased numbers of astrocytes and microglia. Progress in our understanding of the functions of astrocytes suggests that they are efficient antigen-presenting cells, initiating and regulating the intracerebral inflammatory response and limiting parasite spread to the perivascular spaces.     

The composition of air in sleeping bags

The effects of sleeping with one's head inside a conventional arctic sleeping bag at –20°C on body temperature and on the composition of air breathed were investigated. There was little effect on body temperature and concentrations of O₂ and CO₂ levelled off at approximately 16% and 4%, respectively. Changes in the composition of the air breathed by persons using a vapour-barrier sleeping bag and an experimental water-vapour-impermeable liner were also monitored. Concentrations of O₂ and CO₂ of approximately 11% and 6%, respectively, were observed. The possible effects of breathing such air on sleep and thermoregulation are discussed.     

Waking up to sleeping sickness

Devastating epidemics of human African trypanosomiasis are currently re-emerging in many sub-Saharan countries. In the past three decades, clinical research into this important disease has been neglected, as have urgently needed initiatives on drug development, disease surveillance and vector control. Recent impetus has aimed to provide a free supply of antitrypanosomal drugs, to develop a new orally active trypanocidal agent and to attack the tsetse vector with modern technology. In addition, pan-African initiatives to co-ordinate control efforts have begun. These all provide some hope for the future, but they might not be enough to reverse the resurgence of this deadly disease in the heart of Africa.     

An alternative form of melarsoprol in sleeping sickness

Human African trypanosomiasis (HAT), or sleeping sickness, is a major threat to human health throughout sub-Saharan Africa. Almost always fatal if untreated or inadequately treated, a commonly used drug for treating late-stage HAT, and the only drug for late-stage Trypanosoma brucei rhodesiense, is intravenous melarsoprol, which kills 5% of patients receiving it. Melarsoprol cyclodextrin inclusion complexes have been tested in a highly reliable mouse model of HAT. These complexes increase the oral bioavailability of melarsoprol making them effective orally and both curative and nontoxic in doses that are equivalent to those of intravenous melarsoprol. It is argued that a small clinical trial of this drug in HAT is justified to potentially improve the outcome of patients with late-stage rhodesiense disease.